Dr Huw Jones, CEO of TheraCryf plc, on Positive Ox-1 Toxicology Data, Commercial Partner Interest and the Path to Human Trials
15th May 2026TheraCryf plc ( TCF ) is a biotechnology company developing novel treatments for addiction and other neuropsychiatric disorders. Its lead Ox-1 blocker programme is advancing toward first-in-human s...
Follow the stocks